Recent Updates
Recently added Catalysts
ORGO Positive Sentiment

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

Key Takeaway: Organogenesis Holdings Inc. will report its first quarter financial results for fiscal year 2026 on May 7, 2026. A conference call is scheduled for the same day at 5:00 p.m. Eastern Time to discuss these results and provide a corporate update. The call will also include a question and answer session for participants.
Price reaction · baseline $2.24 (2026-04-02 close) · 1 other ORGO headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Organogenesis is a leader in regenerative medicine.
  • The company is set to report financial results, indicating growth.
  • Management will provide a corporate update during the call.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~4 mo
High dilution risk
Lead asset
Amniotic Allograft
Phase 3 · Knee Osteoarthritis

Full Press Release Details

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that first quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, May 7th.
Management will host a conference call at 5:00 p.m. Eastern Time on May 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcasthere,or access the teleconferencehere. The live webcast can also be accessed via the company’s website atinvestors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visitwww.organogenesis.com.

Frequently Asked Questions

When will Organogenesis report its Q1 FY 2026 results?

Organogenesis will report its Q1 FY 2026 financial results on May 7, 2026.

What time is the conference call for Q1 results?

The conference call will take place at 5:00 p.m. Eastern Time on May 7, 2026.

How can I access the conference call?

Participants can access the conference call via a live webcast or teleconference.

Will the conference call be archived?

Yes, the webcast will be archived on the company's website for about one year.

Last updated: Apr 6, 2026